Contact Information

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Emily R Theisen

Research

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies. Publications

                  Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.

                


                  Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  

                


                  Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.

                


                  Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.

                


                  Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.

                


                  Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

Biography

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Awards, Honors & Organizations

Postdoctoral Fellow, Pelotonia, 2016 Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014 Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014 Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013 Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010 Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009 Member, American Association for the Advancement of Science, 2020 - Present Member, American Association for Cancer Research, 2012 - Present Member, American Association of Pharmaceutical Sciences, 2010 - Present

Education

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Connect with Emily R Theisen

Connect on LinkedIn

Connect on Twitter

Contact Information

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Emily R Theisen

Research

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies. Publications

                  Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.

                


                  Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  

                


                  Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.

                


                  Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.

                


                  Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.

                


                  Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

Biography

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Awards, Honors & Organizations

Postdoctoral Fellow, Pelotonia, 2016 Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014 Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014 Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013 Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010 Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009 Member, American Association for the Advancement of Science, 2020 - Present Member, American Association for Cancer Research, 2012 - Present Member, American Association of Pharmaceutical Sciences, 2010 - Present

Education

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Connect with Emily R Theisen

Connect on LinkedIn

Connect on Twitter

Contact Information

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Emily R Theisen

Contact Information

  • Call us at:
  • (614) 355-2995
  • Fax us at:
  • (614) 355-2927
  • Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Emily R Theisen

Research

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies. Publications

                  Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.

                


                  Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  

                


                  Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.

                


                  Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.

                


                  Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.

                


                  Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

Research

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies. Publications

                  Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.

                


                  Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  

                


                  Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.

                


                  Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.

                


                  Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.

                


                  Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

Research

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies. Publications

                  Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.

                


                  Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  

                


                  Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.

                


                  Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.

                


                  Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.

                


                  Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies. Publications

                  Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.

                


                  Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  

                


                  Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.

                


                  Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.

                


                  Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.

                


                  Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

Lab(s)

Center for Childhood Cancer

The Theisen Lab pursues innovative strategies to increase the clinical impact of epigenetic targeted therapies for children with cancer. Specifically, we focus on understanding how context defines different roles for chromatin complexes, with an emphasis on LSD1-containing complexes. We study how specific functions of chromatin complexes interact with disease-specific chromatin context in order to develop novel therapeutic strategies.

Lab(s)

Center for Childhood Cancer

  • Center for Childhood Cancer

                    Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.



                Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;  



                Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.



                Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.



                Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.



                Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

View More Publications

  • Showpnil IA, Selich-Anderson J, Taslim C, Boone MA, Crow JC, Theisen ER, Lessnick SL. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma. Nucleic Acids Res. 2022 Sep 23; 50: 9814-9837.
  • Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. Mol Cancer Res. 2022 Mar 17;
  • Boone MA, Taslim C, Crow JC, Selich-Anderson J, Byrum AK, Showpnil IA, Sunkel BD, Wang M, Stanton BZ, Theisen ER, Lessnick SL. The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. Oncogene. 2021 Jul; 40: 4759-4769.
  • Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 2021 Apr; 16: 405-424.
  • Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes Cancer. 2019 Feb; 10: 21-38.
  • Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proc Natl Acad Sci U S A. 2017 Sep 12; 114: 9870-9875.

Biography

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Biography

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Biography

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Emily Theisen, PhD, is a principal investigator in the Center for Childhood Cancer at The Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of pediatrics at The Ohio State University College of Medicine. Dr. Theisen earned her bachelor’s degree in biology from the University of Wisconsin – Madison, and her PhD in pharmaceutics and pharmaceutical chemistry at the University of Utah College of Pharmacy. There she studied in the Center for Investigational Therapeutics at the Huntsman Cancer Institute, focusing on novel epigenetic targeted agents. She then trained with Dr. Stephen Lessnick in the Center for Childhood Cancer at Nationwide Children’s as a postdoctoral fellow before joining the faculty. Dr. Theisen has spent her career studying pharmacological modulation of chromatin regulators cancer, with a specific focus in pediatric malignancies.

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

  • Center for Childhood Cancer
  • Principal Investigator
  • Primary Department
  • Center for Childhood Cancer

Awards, Honors & Organizations

Postdoctoral Fellow, Pelotonia, 2016 Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014 Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014 Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013 Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010 Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009 Member, American Association for the Advancement of Science, 2020 - Present Member, American Association for Cancer Research, 2012 - Present Member, American Association of Pharmaceutical Sciences, 2010 - Present

Awards, Honors & Organizations

Postdoctoral Fellow, Pelotonia, 2016 Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014 Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014 Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013 Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010 Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009 Member, American Association for the Advancement of Science, 2020 - Present Member, American Association for Cancer Research, 2012 - Present Member, American Association of Pharmaceutical Sciences, 2010 - Present

Awards, Honors & Organizations

Postdoctoral Fellow, Pelotonia, 2016 Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014 Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014 Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013 Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010 Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009 Member, American Association for the Advancement of Science, 2020 - Present Member, American Association for Cancer Research, 2012 - Present Member, American Association of Pharmaceutical Sciences, 2010 - Present

Postdoctoral Fellow, Pelotonia, 2016 Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014 Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014 Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013 Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010 Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009 Member, American Association for the Advancement of Science, 2020 - Present Member, American Association for Cancer Research, 2012 - Present Member, American Association of Pharmaceutical Sciences, 2010 - Present

  • Postdoctoral Fellow, Pelotonia, 2016
  • Women in Cancer Research Scholar in Training, American Association for Cancer Research, 2014
  • Wolf Prize for Teaching and Service, University of Utah College of Pharmacy, 2014
  • Pre-doctoral Fellowship, American Foundation for Pharmaceutical Education, 2013
  • Jeffrey L. Fox Award, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2010
  • Eccles Foundation Fellowship, University of Utah Department of Pharmaceutics and Pharmaceutical Chemistry, 2009
  • Member, American Association for the Advancement of Science, 2020 - Present
  • Member, American Association for Cancer Research, 2012 - Present
  • Member, American Association of Pharmaceutical Sciences, 2010 - Present

Education

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Education

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Education

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Date of Appointment at Nationwide Children’s Hospital: 01/01/2020

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2019

Graduate School

UNIVERSITY OF UTAH SCHOOL OF MEDICINE

Date Completed: 05/15/2015

Undergraduate School

University of Wisconsin-Madison

Date Completed: 05/15/2009

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Center for Childhood Cancer

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-2995

Fax us at: (614) 355-2927

                    700 Children's DriveColumbus, OH 43205 (map)
  • Call us at:
  • (614) 355-2995
  • Fax us at:
  • (614) 355-2927
  • 700 Children’s DriveColumbus, OH 43205 (map)

Connect with Emily R Theisen

Connect on LinkedIn

Connect on Twitter